<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03942484</url>
  </required_header>
  <id_info>
    <org_study_id>BTL-099-S</org_study_id>
    <nct_id>NCT03942484</nct_id>
  </id_info>
  <brief_title>Efficacy of rPMS for Improvement of Urinary Incontinence and Female Sexual Function</brief_title>
  <official_title>Efficacy of Repetitive Pulse Magnetic Stimulation for Improvement of Urinary Incontinence and Female Sexual Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BTL Industries Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BTL Industries Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the repetitive pulse magnetic stimulation (rPMS) for the treatment of urinary
      incontinence and a female sexual satisfaction.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 1, 2019</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of quality of life improvement using the ICIQ-UI questionnaire</measure>
    <time_frame>18 months</time_frame>
    <description>Evaluation of change in ICIQ-UI score. Decrease of the score will be considered as an improvement.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of quality of life improvement using the FSFI questionnaire</measure>
    <time_frame>18 months</time_frame>
    <description>Evaluation of change in FSFI score. Increase of the score will be considered as an improvement.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of quality of life improvement using the PISQ-12 questionnaire</measure>
    <time_frame>18 months</time_frame>
    <description>Evaluation of change in PISQ-12 score. Increase of the score will be considered as an improvement.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety evaluation: Incidence of adverse events (AE) associated with study device will be followed.</measure>
    <time_frame>18 months</time_frame>
    <description>Incidence of adverse events (AE) associated with study device will be followed.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Urinary Incontinence</condition>
  <arm_group>
    <arm_group_label>Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with the investigational device - rPMS</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>rPMS device</intervention_name>
    <description>Pelvic floor muscle contractions will be induced by the device.</description>
    <arm_group_label>Treatment Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 21 and 65 years

          -  Voluntarily signed informed consent form

          -  Suffers from UI

          -  Sexually active

          -  FSFI Questionnaire score â‰¤ 26.55 points

        Exclusion Criteria:

          -  Suffers from other types of urinary incontinence other than SUI, UUI, MUI

          -  Currently lactating

          -  Cardiac pacemakers

          -  Implanted defibrillators and/or neurostimulators

          -  Electronic implants

          -  Metal implants, including copper IUD

          -  Drug pumps

          -  Hemorrhagic conditions

          -  Anticoagulation therapy

          -  Fever

          -  Pregnancy

          -  Following recent surgical procedures when muscle contraction may disrupt the healing
             process

          -  Application over areas of the skin which lack normal sensation
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Julene Samuels</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Joseph Berenholz</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gynecological Solutions</name>
      <address>
        <city>Hillsborough</city>
        <state>New Jersey</state>
        <zip>08844</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Urogynecology</name>
      <address>
        <city>West Columbia</city>
        <state>South Carolina</state>
        <zip>29169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hillcroft Medical Clinic</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77479</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 18, 2019</study_first_submitted>
  <study_first_submitted_qc>May 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2019</study_first_posted>
  <last_update_submitted>May 21, 2020</last_update_submitted>
  <last_update_submitted_qc>May 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

